A detailed history of China Universal Asset Management Co., Ltd. transactions in Verona Pharma PLC stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 21,041 shares of VRNA stock, worth $947,686. This represents 0.07% of its overall portfolio holdings.

Number of Shares
21,041
Previous 15,350 37.07%
Holding current value
$947,686
Previous $221,000 173.76%
% of portfolio
0.07%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$15.46 - $30.16 $87,982 - $171,640
5,691 Added 37.07%
21,041 $605,000
Q2 2024

Jul 19, 2024

SELL
$11.48 - $17.02 $55,678 - $82,547
-4,850 Reduced 24.01%
15,350 $221,000
Q1 2024

Apr 29, 2024

BUY
$15.3 - $20.24 $81,426 - $107,717
5,322 Added 35.77%
20,200 $325,000
Q4 2023

May 21, 2024

SELL
$11.94 - $20.47 $63,544 - $108,941
-5,322 Reduced 26.35%
14,878 $295,000
Q4 2023

Jan 23, 2024

SELL
$11.94 - $20.47 $487,223 - $835,298
-40,806 Reduced 73.28%
14,878 $296,000
Q3 2023

May 21, 2024

BUY
$16.3 - $22.09 $567,419 - $768,974
34,811 Added 166.78%
55,684 $907,000
Q3 2023

Oct 30, 2023

BUY
$16.3 - $22.09 $567,419 - $768,974
34,811 Added 166.78%
55,684 $908,000
Q2 2023

May 21, 2024

BUY
$19.41 - $23.43 $388,413 - $468,857
20,011 Added 2321.46%
20,873 $441,000
Q2 2023

Jul 27, 2023

BUY
$19.41 - $23.43 $388,413 - $468,857
20,011 Added 2321.46%
20,873 $441,000
Q1 2023

May 21, 2024

BUY
$18.06 - $25.27 $4,424 - $6,191
245 Added 39.71%
862 $17,000
Q1 2023

Apr 27, 2023

BUY
$18.06 - $25.27 $4,424 - $6,191
245 Added 39.71%
862 $17,000
Q4 2022

May 21, 2024

SELL
$9.84 - $26.13 $192,696 - $511,703
-19,583 Reduced 96.95%
617 $16,000
Q4 2022

Jan 31, 2023

BUY
$9.84 - $26.13 $6,071 - $16,122
617 New
617 $16,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.75B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.